Lankin V Z, Tikhaze A K, Viigimaa M, Chazova I Е
FSBI "National Medical Research Cardiology Center" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Center for Cardiology of Tallinn University of Technology, Tallinn, Estonia.
Ter Arkh. 2018 Sep 20;90(9):27-30. doi: 10.26442/terarkh201890927-30.
We study the dynamics of oxidatively modified low-density lipoprotein (ox-LDL) content in blood plasma, as well as changes in the activity of key antioxidant enzymes such as Se-containing glutathione peroxidase (GSH-Px) Cu,Zn-superoxide dismutase (SOD) and catalase in erythrocytes of patients with coronary artery disease during treatment with PCSK9 inhibitor (ewolocumab).
The study included 9 men (59 ± 10 years) with coronary artery disease with atherosclerotic lesion at least one main coronary artery according to coronary angiography. Patients took standard therapy before taking the study, everyone took the maximum tolerated dose of statins. Since the target cholesterol levels of low-density lipoprotein cholesterol (LDL-C) were not achieved during the statin therapy, patients were prescribed lipid-lowering therapy with the inclusion of the inhibitor PCSK9-emocoucumab from Amgen 420 mg once a month. The content of lipid metabolism indices was determined by standard biochemical methods. The level of ox-LDL in the blood plasma was determined by the immunochemical method. The activity of antioxidant enzymes was determined in blood erythrocytes using biochemical techniques.
Cholesterol-lowering drug of the new type - inhibitor protein convertase subtilisin/kexin type 9 (PCSK9) evolocumab (Amgen) not only effectively lowers the level of cholesterol in low density lipoprotein (LDL), but also significantly reduces the content of oxdatively modified LDL in blood plasma. Unlike statins, the inhibitor of PCSK9 does not cause a decrease in the activity of antioxidant enzymes of the blood.
PCSK9 inhibitor has no effect on the parameters of oxidative stress.
我们研究了血浆中氧化修饰低密度脂蛋白（ox-LDL）含量的动态变化，以及冠状动脉疾病患者在用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂（依沃克单抗）治疗期间红细胞中含硒谷胱甘肽过氧化物酶（GSH-Px）、铜锌超氧化物歧化酶（SOD）和过氧化氢酶等关键抗氧化酶活性的变化。
该研究纳入了9名男性（59±10岁）冠状动脉疾病患者，根据冠状动脉造影显示至少有一条主要冠状动脉存在动脉粥样硬化病变。患者在参与研究前接受标准治疗，均服用了最大耐受剂量的他汀类药物。由于他汀类治疗期间未达到低密度脂蛋白胆固醇（LDL-C）的目标胆固醇水平，患者被处方了降脂治疗，包括每月一次使用安进公司生产的420mg PCSK9抑制剂依沃克单抗。脂质代谢指标的含量通过标准生化方法测定。血浆中ox-LDL的水平通过免疫化学方法测定。使用生化技术测定血液红细胞中抗氧化酶的活性。
新型降胆固醇药物——前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂依沃克单抗（安进公司）不仅能有效降低低密度脂蛋白（LDL）中的胆固醇水平，还能显著降低血浆中氧化修饰LDL的含量。与他汀类药物不同，PCSK9抑制剂不会导致血液中抗氧化酶活性降低。
PCSK9抑制剂对氧化应激参数无影响。
